Results 321 to 330 of about 121,613 (384)

Cognitive and neurodevelopmental disorders in spinal muscular atrophy type I at the time of disease‐modifying therapies

Developmental Medicine &Child Neurology, EarlyView.
Abstract After treatment with new disease‐modifying therapies, cognitive and neurodevelopmental aspects have been observed in individuals with spinal muscular atrophy (SMA). Emerging evidence suggests that children with SMA type 1 may experience cognitive, language, and behavioural delays, with reported rates of neurodevelopmental difficulties ranging ...
Giorgia Coratti, Bianca Buchignani, Eugenio Mercuri   +2 more
wiley   +1 more source

Beyond motor neurons: autonomic dysfunction and ECG findings in adults with 5q-spinal muscular atrophy. [PDF]

J Neurol
Bacara K, Stojanovic SD, Wohnrade C, Osmanovic A, Schreiber-Katz O, Haghikia A, Petri S, Bjelica B.   +7 more
europepmc   +1 more source

Bilateral laryngeal paralysis (aplegia) occurring late during the recovery of a horse after orthopaedic surgery

Equine Veterinary Education, EarlyView.
Summary A 9‐year‐old male castrated Standardbred was presented for evaluation of a comminuted right front first phalanx fracture. On initial clinical examination, mild haemoconcentration and increased vital parameters were noted. After overnight hospitalisation, the horse underwent general anaesthesia for surgical fracture repair.
I. Lutvikadic, K. Hopster, B. Driessen
wiley   +1 more source

Respiratory effects of nusinersen treatment in pediatric patients with spinal muscular atrophy types 2 and 3. [PDF]

Eur J Pediatr
Rochman M, Shay Levanon D, Amirav I, Be'er M, Cahal M, Besor O, Fattal-Valevski A, Lavie M.   +7 more
europepmc   +1 more source

Evaluating Therapeutic Outcomes in Spinal Muscular Atrophy: An Indian Experience. [PDF]

Ann Indian Acad Neurol
Mohanlal S, Mubeena PM, Hussain H, Anand M, Kumar S, Ashraf VV, Rabia TA, Janardhanan S, Kumar S.   +8 more
europepmc   +1 more source

Single Nucleotide <i>SMN1</i> Variants in a Cohort of Individuals With Spinal Muscular Atrophy. [PDF]

Neurol Genet
Rimoldi M, Magri F, Meneri M, Gagliardi D, Ada Sansone V, Albamonte E, Ottoboni L, Comi GP, Mercuri E, Tiziano FD, Ronchi D, Corti S.   +11 more
europepmc   +1 more source

Comparative Clinical Outcomes of Nusinersen and Gene Therapy in Spinal Muscular Atrophy Type 1.

JAMA Netw Open
Ropars J, Cances C, Garcia-Uzquiano R, Gomez-Garcia de la Banda M, Barnerias C, Audic F, Durigneux J, Halbert C, Nkam L, Laugel V, Espil C, Walther-Louvier U, Davion JB, Isapof A, Le Goff L, Desguerre I, Quijano-Roy S, Grimaldi L, French SMA Registry Study Group.   +18 more
europepmc   +1 more source

Machine learning predicts treatment response to nusinersen in non-sitter Spinal Muscular Atrophy (SMA).

Stimpson G, O'Reilly E, Coratti G, Ridout D, Chakraborti T, Mitra R, de Sanctis R, Pane M, Scoto M, Mercuri E, Muntoni F, Baranello G, International SMA Consortium.   +12 more
europepmc   +1 more source